FDA Should Speed Waiver Process For Lot Release Tests During Emergencies
This article was originally published in The Gray Sheet
Executive Summary
The Federal Office of Homeland Security should coordinate the distribution of diagnostic equipment and other blood testing products during emergencies, according to Johnson & Johnson/Ortho-Clinical Diagnostics' Director of Reimbursement and Health Policy Susan Reardon
You may also be interested in...
House Med Tech Caucus Meeting Spotlights Rapid Anthrax Diagnostic
Roche Diagnostics anticipates it will be able to manufacture sufficient quantities of its rapid anthrax test until December to meet U.S. demand
Device Center Emergency Preparedness Policy Team Includes Gill, Pellerite
CDRH Acting Deputy Director for Science Lillian Gill will lead the center's policy development team for emergency preparedness. The group will develop procedures for the center to follow in responding to a terrorist attack
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”